Symbol Lookup

Friday January 20, 2017 11:02 AM ET. Data delayed 15 minutes.
11.38
-0.22 (-1.90%)
Bid/Lots
11.38/4
Ask/Lots
11.42/1
Open/Prev Close
11.60/11.60
Day Range
11.25-11.75
52-Week Range
4.26-12.74
Vol/Avg Daily Vol
404.1K/1.1M

TD Waterhouse offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

CARA Headlines

Go
2017 Legal Cannabis Market Developments
9:00AM ET on Wednesday Jan 11, 2017 by PR Newswire
Companies Mentioned: INSY, GWPH, CARA, MSRT, ZYNE

http://www.Financialbuzz.com - The future of the legal cannabis market depends on a variety of factors. Politically, some have expressed concerns regarding the incoming elected administration, others feel more optimistic after nine states have voted this election cycle. The results overwhelmingly came in favor of legalization of cannabis for medical and recreational use. Economically, the industry has shown tremendous growth year to year. According to a research published on January 3rd 2017 by ArcView Group, the legal cannabis sales in the U.S. last year reached $6.7 billion, a growth of 30 percent from 2015. Sales are projected to increase to $20.2 billion by the year 2021 representing a 25 percent compound annual growth rate. MassRoots, Inc. (OTC: MSRT), Cara Therapeutics Inc. (NASDAQ: CARA), Insys Therapeutics Inc. (NASDAQ: INSY), GW Pharmaceuticals (NASDAQ: GWPH), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE)

http://www.Financialbuzz.com - The future of the legal cannabis market depends on a variety of factors. Politically, some have expressed concerns regarding the incoming elected administration, others feel more optimistic after nine states have ...

Jan 10, 2017

Research Reports Coverage on Biotech Stocks -- Cara Therapeutics, Heat Biologics, Vanda Pharma, and Opexa Therapeutics
7:40AM ET on Tuesday Jan 10, 2017 by PR Newswire
Companies Mentioned: OPXA, VNDA, HTBX, CARA

For today, Stock-Callers.com takes a closer look at some Biotech equities: Cara Therapeutics Inc. (NASDAQ: CARA), Heat Biologics Inc. (NASDAQ: HTBX), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), and Opexa Therapeutics Inc. (NASDAQ: OPXA). These companies are part of the Healthcare sector which posted moderate gains during afternoon trade on Monday, January 09th, 2017. As per an article on NASDAQ, the NYSE Health Care Index increased about 0.5%, while shares of health care companies in the S&P 500 also were up about 0.5% as a group. These stocks research reports can be downloaded now by simply registering for free at:

For today, Stock-Callers.com takes a closer look at some Biotech equities: Cara Therapeutics Inc. (NASDAQ: CARA), Heat Biologics Inc. (NASDAQ: HTBX), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), and Opexa Therapeutics Inc. (NASDAQ: OPXA). These c...

Jan 5, 2017

The Cannabis Market Enters 2017 on a Strong Footing
9:00AM ET on Thursday Jan 05, 2017 by PR Newswire
Companies Mentioned: INSY, CIIX, GWPH, CARA, ZYNE

http://www.Financialbuzz.com - Over the recent few years, particularly in 2016, the legal cannabis industry has accomplished some significant milestones. Most importantly is the change of public opinion regarding the use of cannabis, both for medical and recreational purposes. Before the November 8th elections where five states voted on legislation reform, a Gallup poll showed that 60% of Americans support legal cannabis use. According to the poll, that is the largest percentage of support for legalization ever in the recorded 47-years of studies conducted, with support increasing among all age groups. ChineseInvestors.com, Inc. (OTC: CIIX), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE), GW Pharmaceuticals (NASDAQ: GWPH), Cara Therapeutics Inc. (NASDAQ: CARA), Insys Therapeutics Inc. (NASDAQ: INSY).

http://www.Financialbuzz.com - Over the recent few years, particularly in 2016, the legal cannabis industry has accomplished some significant milestones. Most importantly is the change of public opinion regarding the use of cannabis, both for m...

Dec 23, 2016

The Mainstream Growth of the Cannabidiol Market
9:00AM ET on Friday Dec 23, 2016 by PR Newswire
Companies Mentioned: CBDS, GWPH, CARA, IVITF, ZYNE

The legal cannabis market is expanding at a rapid pace. This year five states voted to legalize cannabis for recreational use. In four of these states the proposition passed. Currently 15 states only allow Cannabidiol and alongside that, there are 28 states and District of Columbia that have legalized all forms of medical marijuana. According to a recent report published by The Hemp Business Journal, the Cannabidiol market will grow to a $2.1 billion market in consumer sales by 2020 with $450 million of those sales coming from hemp-based sources. That's a rapid increase from 2016, as projections for 2016 indicate the hemp-derived CBD market is poised to reach a value of $115 million by the end of the year. Invictus MD Strategies Corp. (OTC: IVITF) (CSE: IMH.CN), Cara Therapeutics Inc. (NASDAQ: CARA), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE), GW Pharmaceuticals (NASDAQ: GWPH), Cannabis Sativa Inc. (OTC: CBDS)

The legal cannabis market is expanding at a rapid pace. This year five states voted to legalize cannabis for recreational use. In four of these states the proposition passed. Currently 15 states only allow Cannabidiol and alongside that, there ...

Peers Headlines

Jan 9, 2017

BRIEF-Sorrento Therapeutics unit says key endpoints met in EU Pivotal Bioequivalence Clinical Study for ZTlido
10:28AM ET on Monday Jan 09, 2017 by Thomson Reuters
Companies Mentioned: SRNE

Jan 9 (Reuters) - Sorrento Therapeutics Inc -

* Sorrento subsidiary, Scilex Pharmaceuticals, announces key endpoints met in the European Union Pivotal ...

Sorrento Unit Says Study On Patch For Post-Herpetic Neuralgia Met Key Endpoints
9:13AM ET on Monday Jan 09, 2017 by MT Newswires
Companies Mentioned: SRNE
09:13 AM EST, 01/09/2017 (MT Newswires) -- Sorrento Therapeutics' (SRNE) SCILEX Pharmaceuticals unit said pre-market Monday that a study on lead investigational product ZTlido met primary and secondary endpoints. ZTlido is a patch currently bein...
Sorrento Subsidiary, SCILEX Pharmaceuticals, Announces Key Endpoints Met in the European Union Pivotal Bioequivalence Clinical Study for Its Lead Product, ZTlido(TM)
9:00AM ET on Monday Jan 09, 2017 by PR Newswire
Companies Mentioned: SRNE

SCILEX Pharmaceuticals Inc. ("SCILEX"), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") today announced that its pivotal study for its lead investigational product, ZTlido(TM) (lidocaine patch 1.8%), has met a primary end...

Jan 5, 2017

BRIEF-Sorrento Therapeutics says entered into warrant and note cancellation and share forfeiture agreements - SEC filing
5:49PM ET on Thursday Jan 05, 2017 by Thomson Reuters
Companies Mentioned: SRNE

Jan 5 (Reuters) - Sorrento Therapeutics Inc

* On Dec 31, co entered into warrant and note cancellation and share forfeiture agreements - SEC filing

* So...

Jan 4, 2017

Trevena Completes Enrollment of Trials of Oliceridine for Moderate-to-Severe Acute Pain
7:20AM ET on Wednesday Jan 04, 2017 by MT Newswires
Companies Mentioned: TRVN
07:20 AM EST, 01/04/2017 (MT Newswires) -- Biopharmaceutical company Trevena (TRVN) said Wednesday it has completed enrollment of its studies of oliceridine (TRV130) in moderate-to-severe acute pain following bunionectomy and abdominoplasty. The ...
Trevena Completes Enrollment of Phase 3 APOLLO Pivotal Efficacy Trials of Oliceridine for Moderate-to-Severe Acute Pain
7:00AM ET on Wednesday Jan 04, 2017 by GlobeNewswire
Companies Mentioned: TRVN

Trevena, Inc. (NASDAQ:TRVN) today announced that it has completed enrollment of its Phase 3 APOLLO-1 and APOLLO-2 pivotal efficacy studies of oliceridine (TRV130) in moderate-to-severe acute pain following bunionectomy and abdominoplasty, respe...

Dec 21, 2016

Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
8:30AM ET on Wednesday Dec 21, 2016 by Business Wire
Companies Mentioned: SRNE, CRIS

Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a group of the top 30 companies developing cancer immunotherapy treatments and dis...